Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Gusenleitner

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Cell|April 17, 2018
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeSachet A Shukla, Pavan Bachireddy, Bastian Schilling, et al.
Blood|September 2, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaGabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Cell|April 17, 2018
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeSachet A Shukla, Pavan Bachireddy, Bastian Schilling, et al.
Blood|September 2, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaGabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, et al.
Blood|December 25, 2015
Targetable genetic features of primary testicular and primary central nervous system lymphomasBjoern Chapuy, Margaretha G M Roemer, Chip Stewart, et al.
Pageof 3